Results
1 -
10 of
207Sabrina Touchet, François Carreaux, Bertrand Carboni, Alexandre Bouillon and Jean-Luc Boucher.
Aminoboronic acids and esters: from synthetic challenges to the discovery of unique classes of enzyme inhibitors, Chem. Soc. Rev., 2011, 40, 3895. Berkley E. Gryder, Will Guerrant, Chin Ho Chen and Adegboyega K. Oyelere.
Oxathiazole-2-one derivative of bortezomib: Synthesis, stability and proteasome inhibition activity, Med. Chem. Commun., 2011, 2, 1083. Sreedhar Pamu, Di Chen, Fred Morin, Congde Huo, Qiuzhi Cui, Q. Ping Dou and Tak Hang Chan.
Inhibitory effect of bortezomib on human multiple myeloma cells when combined with epigallocatechin-gallate (EGCG) analogs, Med. Chem. Commun., 2012, 3, 229. Martijn Verdoes, Bogdan I. Florea, Wouter A. van der Linden, Didier Renou, Adrianus M. C. H. van den Nieuwendijk, Gijs A. van der Marel and Herman S. Overkleeft.
Mixing of peptides and electrophilic traps gives rise to potent, broad-spectrum proteasome inhibitors, Org. Biomol. Chem., 2007, 5, 1416. Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients, Cancer Chemotherapy and Pharmacology Bortezomib resistance in multiple myeloma is associated with increased serine synthesis, Cancer & Metabolism Delayed treatment with vitamin C and N-acetyl-l-cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib, International Journal of Hematology